CCR1
C-C chemokine receptor type 1
As of the edition of 20 October 2026, CCR1 (C-C chemokine receptor type 1, UniProt P32246) has 3 drugs tested at it and 3 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P32246
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 3
- Disease areas
- Bones, joints and muscles; Immune system; Skin and connective tissue; Lungs and airways
- Registered trials of its drugs
- 5
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| AZD4818 | Went quiet | Phase 2 | none listed |
| CCX354 | Went quiet | Phase 2 | none listed |
| BMS-817399 | Went quiet | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Amgen | Route A |
| AstraZeneca | Route A |
| Bristol Myers Squibb | Route A |
The other 0 companies at CCR1
In the product3 companies in all; 0 are not named here, and no score is.
See the 3 companies at CCR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.